Cabozantinib (XL184) is a drug that blocks several proteins (called MET, RET, and vascular endothelial growth factor receptor 2) that help keep cancer cells alive. It is approved for treating thyroid cancer, and has shown promise against liver cancer in prior clinical trials.
In this study, researchers are comparing the effectiveness of cabozantinib versus a placebo (inactive pill) in patients with advanced hepatocellular carcinoma (liver cancer) whose disease persists despite prior treatment with the drug sorafenib. Patients will be randomly assigned to receive cabozantinib or a placebo in a 2:1 ratio. This means that two-thirds of the patients will receive cabozantinib, and one-third will receive a placebo.